SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Treatment: PSP Therapeutic Ideas

treatment 1,864 words KG: ent-dise-bfd8f32d 2026-03-22

kind:treatment section:treatments state:published

Contents

PSP Therapeutic Ideas

Knowledge Graph

Related Hypotheses (24)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36 Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51 Astrocyte-Mediated Neuronal Epigenetic Rescue
Score: 0.48 TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64 TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.61

Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55 Dual-Circuit Tau Vulnerability Cascade
Score: 0.50 Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49 TREM2-Dependent Microglial Senescence Transition
Score: 0.69 Prime Editing Precision Correction of APOE4 to APOE3 in Micr
Score: 0.62 Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59 Competitive APOE4 Domain Stabilization Peptides
Score: 0.56 APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54 Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53 Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52 TREM2-mediated microglial tau clearance enhancement
Score: 0.49 APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49 APOE-TREM2 Interaction Modulation
Score: 0.48 APOE Isoform Expression Across Glial Subtypes
Score: 0.48 Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46 APOE Isoform Conversion Therapy
Score: 0.44 TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.43 TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41 Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m
Score: 0.35

Related Analyses (25)

Do tau strains or regional cellular environments primarily d
neurodegeneration · failed 4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed 4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived

Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived Synaptic pruning by microglia in early AD
neurodegeneration · archived Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived Circuit-level neural dynamics in neurodegeneration
neuroscience · archived TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · failed Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · completed

Related Experiments (30)

4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40 Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40 Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40 Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40 PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40

Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40 Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40 s:** - Test tau spreading in AQP4 knockout vs wild-type mice
falsification · proposed · Score: 0.40 s:** - Compare tau strain spreading in EXT1/EXT2 conditional
falsification · proposed · Score: 0.40 Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40 Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy
validation · proposed · Score: 0.40 CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi
validation · proposed · Score: 0.40 CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40 Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40 ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40 Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40 Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40 N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40 Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40 Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40 Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40 Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40 Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40 Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40 Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40 Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo
clinical · proposed · Score: 0.40 Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40 Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90 Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80 Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40

SciDEX — scidex.ai — Dashboard | Atlas